2025-02-08 - Analysis Report
## Eli Lilly and Co (LLY) Stock Report

**0) Executive Summary:**

Eli Lilly and Co (LLY) is a leading pharmaceutical company.  Its stock has significantly outperformed the S&P 500 (VOO) over various periods, showing strong growth and profitability.  However, recent high RSI and price action warrant caution.

**1) Performance Comparison:**

Eli Lilly and Co. (LLY) has shown substantially higher cumulative returns (633.99%) compared to the S&P 500 (VOO) at 120.63%.  The divergence is significant (513.4 points), placing it at the 81.6th percentile of its historical range relative to the S&P 500.  The provided alpha and beta data suggest periods of both strong outperformance (high alpha) and market correlation (beta near 1).  Note that the extremely high CAGR values in the table suggest a highly skewed dataset possibly focused on particular periods of exceptional growth.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha | Beta | Cap(B) |
|------------|----------|----------|-------|-------|--------|
| 2015-2017  | 9.0%     | 4.3%     | -0.0   | 68.6  |        |
| 2016-2018  | 47.0%    | 4.3%     | 0.0   | 96.4  |        |
| 2017-2019  | 60.0%    | 8.7%     | 1.1   | 112.0 |        |
| 2018-2020  | 90.0%    | 11.1%    | 0.3   | 146.7 |        |
| 2019-2021  | 145.0%   | 11.1%    | 0.2   | 243.6 |        |
| 2020-2022  | 196.0%   | 11.1%    | 0.2   | 327.1 |        |
| 2021-2023  | 300.0%   | 10.8%    | 0.3   | 526.3 |        |
| 2022-2024  | 396.0%   | 11.1%    | 0.3   | 701.6 |        |
| 2023-2025  | 390.0%   | 11.1%    | 0.3   | 791.0 |        |


**2) Recent Price Movement:**

* **Closing Price:** $870.37
* **Last Market Price:** $880.61 (a $1.18 increase)
* **5-Day Moving Average:** $832.03
* **20-Day Moving Average:** $790.43
* **60-Day Moving Average:** $786.54

The price is above all moving averages, suggesting a bullish trend.  The recent price increase shows a short-term positive momentum.

**3) Technical Indicators:**

* **RSI:** 76.81 (Overbought territory, suggesting potential short-term correction)
* **PPO:** 1.21 (Positive, indicating bullish momentum)
* **Delta_Previous_Relative_Divergence:** +5.3 (Short-term upward trend)

The high RSI value indicates the stock is currently overbought and may be due for a correction.  The recent price increase (880.61 > 870.37) confirms a short-term upward trend but also signals the potential for a short-term correction due to the overbought condition.

**Expected Return:** 94.1% (long-term, >2 years, relative to S&P 500). This is a very high expected return and should be considered with caution due to inherent uncertainty in any long term prediction.

**4) Recent Earnings Analysis:**

| Date       | EPS      | Revenue      |
|------------|----------|--------------|
| 2024-10-30 | $1.08    | $11.44B      |
| 2024-08-08 | $3.29    | $11.30B      |
| 2024-04-30 | $2.49    | $8.77B       |
| 2023-11-02 | -$0.06   | $9.50B       |
| 2024-10-30 | -$0.06   | $9.50B       |

Earnings show some volatility, with a significant jump in EPS in August 2024.  There is a duplicate entry for October 2024 which needs clarification.  Further investigation into the discrepancies is needed.

**5) Financial Information:**


**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |
| 2023-12-31 | $9.35B    | 80.88%        |
| 2023-09-30 | $9.50B    | 80.42%        |

**Capital and Profitability:**

| Quarter | Equity     | ROE           |
|---------|------------|---------------|
| 2024-09-30 | $14.24B   | 6.81%         |
| 2024-06-30 | $13.56B   | 21.88%        |
| 2024-03-31 | $12.81B   | 17.51%        |
| 2023-12-31 | $10.77B   | 20.33%        |
| 2023-09-30 | $11.22B   | -0.51%        |

The company demonstrates strong and consistent revenue and high profit margins. ROE shows some variability, possibly influenced by factors not reflected in the data provided.  Further analysis is needed.



**6) Overall Analysis:**

LLY has demonstrated exceptional performance compared to the S&P 500, driven by strong earnings and profitability. However, the current high RSI suggests the stock might be overbought and prone to a short-term correction. The provided CAGR figures are extraordinarily high and need further examination of the underlying data.  The inconsistent and potentially erroneous earnings data requires further investigation.  While long-term prospects seem positive, caution is advised given the current overbought condition and the need for clarification on the provided data.  A deeper dive into the fundamental and technical aspects is recommended before making any investment decisions.
